Stock Taper
SNTI
SENTI BIOSCIENCES, INC.
NASDAQ
$0.38
▼ DOWN 0.13% (-0.00)

KEY STATISTICS

Market Cap$11.74 M
52w High$2.88
52w Low$0.33
Dividend Yield
Frequency
P/E-0.21
Volume90.81K
Shares Out.31.14M

COMPANY

LEADERSHIP

Timothy K. Lu
CHIEF EXECUTIVE
Timothy K. Lu

COMPENSATION 2026

Salary$618,757
Stock Awards$140,760
Incentive Plan Pay$442,412
All Other Comp.$12,031
Total$930,690

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 26, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
39

PRICE TARGET

Target High$6.00
Target Low$6.00
Target Median$6.00
Target Consensus$6.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$15.87K
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2024-07-18Reverse1:10

PRICE

$0.38 ▼ DOWN 0.13% (−$0.00)
OVERLAYS
$0.37$0.38$0.38$0.399:33 AM10:37 AM11:42 AM12:46 PM1:50 PM2:55 PM3:59 PM0.38

About Senti Biosciences, Inc.

https://www.sentibio.com ↗

Senti Biosciences develops gene circuit-based cell therapies, including off-the-shelf CAR-NK treatments targeting cancers like AML, HCC, and CRC through engineered biological logic to precisely reprogram immune responses.

INDUSTRY

Biotechnology

A PRODUCT SENTI BIOSCIENCES, INC. IS KNOWN FOR

SENTI-202
SENTI-202

SENTI-202 is a clinical-stage off-the-shelf CAR-NK therapy targeting CD33 and FLT3 for AML and blood cancers, recently completed Phase 1 enrollment and received FDA RMAT designation.

Revenue by Products

IconPRODUCTQ1-2023Q2-2023Q2-2026
License$400K $200K
Reportable Segment$17K

ETFS HOLDING THIS STOCK

ETFS HOLDING
11
LISTED HERE
1
RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED
0.99%
HOLDERS
3
TOP 3 OF 3 · RANKED BY POSITION SIZE
8vc Gp I, LLC
253.8K sh · $357.8K
Blackrock Inc.
40.1K sh · $11.05K
Triatomic Management LP
15.5K sh · $4.28K

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

OFFICER: PRES. & CHIEF MED. & DEV. OFF.
Rajangam Kanya
Sale · 10.8K shares
2026-03-09
DIRECTOR, OFFICER: CEO
Lu Timothy K
Sale · 80.7K shares
2026-03-09
OFFICER: PRES. & CHIEF MED. & DEV. OFF.
Rajangam Kanya
Sale · 1.4K shares
2026-02-02
DIRECTOR, OFFICER: CEO
Lu Timothy K
Sale · 4.2K shares
2026-02-02

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS

SECTORS PEERS

PEERPRICE
XFOR$4.04COMPARE
IPSC$2.02COMPARE
CUE$27.88COMPARE
ALGS$6.91COMPARE
KPTI$1.87COMPARE
BRNS$0.75COMPARE
GNTA$1.00COMPARE
MDCX$0.26COMPARE